Outlook Therapeutics, Inc. OTLKW 深 滬
等待開盤 08-07 09:30:00 美东时间
0.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 總市值 8.75万
- 52周最高 1.27
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 總股本 291.70万
- 歷史最高 3.49
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.01
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Outlook Therapeutics announces CEO appointment
Outlook Therapeutics (NASDAQ:OTLK) has named Bob Jahr as chief executive officer and a member of its board. Jahr succeeds interim CEO Lawrence A. Kenyon, who will continue as chief financial officer a...
07-01 20:22
Outlook Therapeutics Appoints Bob Jahr As CEO
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographiesCareer focused on driving business growth and developing an integrated
07-01 20:12
Rubrik To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
06-06 20:51
Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab
06-02 19:09
Outlook Therapeutics Reports Improved Financials Amid Challenges
Outlook Therapeutics ( ($OTLK) ) has released its Q2 earnings. Here is a breakd...
05-23 11:52
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
Outlook Therapeutics shares are trading lower after the company announced a proposed public offering.
Outlook Therapeutics shares are trading lower after the company announced a pro...
05-23 04:02
Outlook Therapeutics Q2 Adj. EPS $(0.40) Beats $(0.60) Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.60) by 33.33 percent. This is a 74.19 percent increase over losses of $(1.55) per share
05-16 04:11
Outlook Therapeutics Approves Retention Incentive for CFO
Outlook Therapeutics ( ($OTLK) ) just unveiled an update. On April 9, 2025, Out...
04-12 06:22
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment
Outlook Therapeutics (NASDAQ:OTLK) said on Tuesday that the U.S. FDA has accepted to review ONS-5010, an ophthalmic formulation of bevacizumab, for the treatment of wet age-related macular degeneratio...
04-08 22:42
